Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations

References

• Liao S-H, Su T-H, Jeng Y-M, Liang P-C, Chen D-S, Chen C-H, Kao J-H. Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology. 2019;69(1):209–221.
   PubMed Web of Science ®Google Scholar
• Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 2017;1868(2):564–570.
   PubMed Web of Science ®Google Scholar
• Li J-j, Liang Q, Sun G-c. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: a focus on epithelial-mesenchymal transition. J Integr Med. 2021;19(6):469–477.
   PubMedGoogle Scholar
• Cidon EU. Systemic treatment of hepatocellular carcinoma: past, present and future. World J Hepatol. 2017;9(18):797–807.
   PubMedGoogle Scholar
• Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33(1):139–189.
   PubMed Web of Science ®Google Scholar
• Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, Liu B. Small-molecule drug discovery in triple negative breast cancer: current situation and future directions. J Med Chem. 2021;64(5):2382–2418.
   PubMed Web of Science ®Google Scholar
• Pourkavoos N. Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. combprodther. 2012;2(1):2.
   Google Scholar
• Thakur A, Tawa GJ, Henderson MJ, Danchik C, Liu S, Shah P, Wang AQ, Dunn G, Kabir M, Padilha EC, et al. Design, Synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as dual PI3K/HDAC inhibitors. J Med Chem. 2020;63(8):4256–4292.
   PubMed Web of Science ®Google Scholar
• Zhang W, Pei J, Lai L. Computational multitarget drug design. J Chem Inf Model. 2017;57(3):403–412.
   PubMed Web of Science ®Google Scholar
• Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7(1):3.
   PubMed Web of Science ®Google Scholar
• Liu X-J, Zhao H-C, Hou S-J, Zhang H-J, Cheng L, Yuan S, Zhang L-R, Song J, Zhang S-Y, Chen S-W, et al. Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy. Bioorg Chem. 2023;133:106425.
   PubMed Web of Science ®Google Scholar
• Rodriguez Y, Hinz JM, Smerdon MJ. Accessing DNA damage in chromatin: preparing the chromatin landscape for base excision repair. DNA Repair. 2015;32:113–119.
   PubMed Web of Science ®Google Scholar
• Hai Y, Christianson DW. Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nat Chem Biol. 2016;12(9):741–747.
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–176.
   PubMed Web of Science ®Google Scholar
• Schneider G, Kramer OH, Schmid RM, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer. 2011;42(2):85–92.
   PubMedGoogle Scholar
• Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8(1):381.
   PubMedGoogle Scholar
• Wang Y, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z. Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site. Cell Death Dis. 2021;12(1):55.
   PubMed Web of Science ®Google Scholar
• Kim HS, Chang YG, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Lee EK, Park S, Ahn YM, et al. Oncogenic potential of CK2alpha and its regulatory role in EGF-induced HDAC2 expression in human liver cancer. Febs J. 2014;281(3):851–861.
   PubMed Web of Science ®Google Scholar
• Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007;67(7):3145–3152.
   PubMed Web of Science ®Google Scholar
• Gao B, Li X, Li S, Wang S, Wu J, Li J. Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker. Phenomics. 2022;2(1):33–49.
   PubMedGoogle Scholar
• Han R, Ling C, Wang Y, Lu L. Enhancing HCC treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition. Cancer Cell Int. 2023;23(1):203.
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Seo D, Choi K-J, Andersen JB, Won M-A, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, et al. Antitumor effects in Hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res. 2014;74(17):4752–4761.
   PubMed Web of Science ®Google Scholar
• Mohammad NS, Nazli R, Zafar H, Fatima S. Effects of lipid based multiple micronutrients supplement on the birth outcome of underweight pre-eclamptic women: a randomized clinical trial. Pak J Med Sci. 2022;38(1):219–226.
   PubMed Web of Science ®Google Scholar
• Ler SY, Leung CHW, Khin LW, Lu G-D, Salto-Tellez M, Hartman M, Iau PTC, Yap CT, Hooi SC. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep. 2015;34(5):2238–2250.
   PubMed Web of Science ®Google Scholar
• Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park WS, Lee JY, et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One. 2011;6(11):e28103.
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Chen C-C, Chuang W-Y, Leu Y-L, Ueng S-H, Hsueh C, Yeh C-T, Wang T-H. Hydroxygenkwanin inhibits class I HDAC expression and synergistically enhances the antitumor activity of Sorafenib in liver cancer cells. Front Oncol. 2020;10:216.
   PubMed Web of Science ®Google Scholar
• Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol. 2012;13(2):115–126.
   PubMed Web of Science ®Google Scholar
• Chen R, Chen Y, Zhao W, Fang C, Zhou W, Yang X, Ji M. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. Onco Targets Ther. 2020;13:6837–6846.
   PubMed Web of Science ®Google Scholar
• Topchu I, Pangeni RP, Bychkov I, Miller SA, Izumchenko E, Yu J, Golemis E, Karanicolas J, Boumber Y. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cell Mol Life Sci. 2022;79(6):285.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang H, Su M, Lian F, Cong Z, Wei R, Zhou Y, Li X, Zheng X, Li C, et al. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma. Eur J Med Chem. 2021;222:113592.
   PubMed Web of Science ®Google Scholar
• Gao B, Liu X, Li Z, Zhao L, Pan Y. Overexpression of EZH2/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in triple-negative breast cancer. Front Oncol. 2020;10:600514.
   PubMed Web of Science ®Google Scholar
• Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang H-e. C, Taylor JE, Hu M, Englund NP, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet. 2013;45(11):1386–1391.
   PubMed Web of Science ®Google Scholar
• Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, et al. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 2014;28(1):198–201.
   PubMed Web of Science ®Google Scholar
• Zhao L-H, Li Q, Huang Z-J, Sun M-X, Lu J-J, Zhang X-H, Li G, Wu F. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer. Cell Death Dis. 2021;12(11):974.
   PubMed Web of Science ®Google Scholar
• Song D, Lan J, Chen Y, Liu A, Wu Q, Zhao C, Feng Y, Wang J, Luo X, Cao Z, et al. NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein. Oncogene. 2021;40(16):2952–2967.
   PubMed Web of Science ®Google Scholar
• Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung H-J, Gao AC, Zou JX, Chen H-W, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012;32(15):3121–3131.
   PubMed Web of Science ®Google Scholar
• Dai J, Jiang L, Qiu L, Shao Y, Shi P, Li J. WHSC1 promotes cell proliferation, migration, and invasion in hepatocellular carcinoma by activating mTORC1 signaling. Onco Targets Ther. 2020;13:7033–7044.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zha X. Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives. Eur J Med Chem. 2023;250:115232.
   PubMed Web of Science ®Google Scholar
• Ferreira de Freitas R, Liu Y, Szewczyk MM, Mehta N, Li F, McLeod D, Zepeda-Velázquez C, Dilworth D, Hanley RP, Gibson E, et al. Discovery of small-molecule antagonists of the PWWP domain of NSD2. J Med Chem. 2021;64(3):1584–1592.
   PubMed Web of Science ®Google Scholar
• Li N, Yang H, Liu K, Zhou L, Huang Y, Cao D, Li Y, Sun Y, Yu A, Du Z, et al. Structure-based discovery of a series of NSD2-PWWP1 inhibitors. J Med Chem. 2022;65(13):9459–9477.
   PubMedGoogle Scholar
• Tang H, Yu A, Xing L, Chen X, Ding H, Yang H, Song Z, Shi Q, Geng M, Huang X, et al. Structural modification and pharmacological evaluation of substituted quinoline-5,8-diones as potent NSD2 inhibitors. J Med Chem. 2023;66(2):1634–1651.
   PubMed Web of Science ®Google Scholar
• Hanley RP, Nie DY, Tabor JR, Li F, Sobh A, Xu C, Barker NK, Dilworth D, Hajian T, Gibson E, et al. Discovery of a potent and selective targeted NSD2 degrader for the reduction of H3K36me2. J Am Chem Soc. 2023;145(14):8176–8188.
   PubMed Web of Science ®Google Scholar
• Wan G, Feng Z, Zhang Q, Li X, Ran K, Feng H, Luo T, Zhou S, Su C, Wei W, et al. Design and synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) dual inhibitors for the treatment of cancer. J Med Chem. 2022;65(24):16541–16569.
   PubMed Web of Science ®Google Scholar
• Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood. 2007;110(7):2667–2673.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21(21):4767–4773.
   PubMed Web of Science ®Google Scholar
• Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, et al. Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK/HDAC dual inhibitors for the treatment of refractory solid tumors. J Med Chem. 2022;65(2):1243–1264.
   PubMed Web of Science ®Google Scholar
• Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min D-J, Will C, Neri A, Kelleher NL, Yu J, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer. Oncogene. 2012;32(23):2882–2890.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114(13):2733–2743.
   PubMed Web of Science ®Google Scholar
• Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83–98.
   PubMed Web of Science ®Google Scholar
• Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, Kaplan SA, Smith NL, Khan SA. The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis. 2018;21(1):22–36.
   PubMed Web of Science ®Google Scholar
• Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14(9):603–622.
   PubMed Web of Science ®Google Scholar
• Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res. 2015;38(9):1686–1701.
   PubMed Web of Science ®Google Scholar
• Maia EHB, Assis LC, de Oliveira TA, da Silva AM, Taranto AG. Structure-based virtual screening: from classical to artificial intelligence. Front Chem. 2020;8:343.
   PubMed Web of Science ®Google Scholar
• Yang D‐S, Yang Y‐H, Zhou Y, Yu L‐L, Wang R‐H, Di B, Niu M‐M. A redox‐triggered bispecific supramolecular nanomedicine based on peptide self‐assembly for high‐efficacy and low‐toxic cancer therapy. Adv Funct Materials. 2019;30(4): 1904969.
   Web of Science ®Google Scholar
• Zhou Y, Zou Y, Yang M, Mei S, Liu X, Han H, Zhang C-D, Niu M-M. Highly potent, selective, biostable, and cell-permeable cyclic d-peptide for dual-targeting therapy of lung cancer. J Am Chem Soc. 2022;144(16):7117–7128.
   PubMed Web of Science ®Google Scholar
• Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, et al. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle. 2012;11(17):3250–3259.
   PubMed Web of Science ®Google Scholar
• Thiyagarajan V, Lin SH, Chang YC, Weng CF. Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking. Biomed Pharmacother. 2016;80:52–62.
   PubMed Web of Science ®Google Scholar
• Chao M-W, Lin TE, HuangFu W-C, Chang C-D, Tu H-J, Chen L-C, Yen S-C, Sung T-Y, Huang W-J, Yang C-R, et al. Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach. J Enzyme Inhib Med Chem. 2021;36(1):98–108.
   PubMed Web of Science ®Google Scholar
• Opo F, Rahman MM, Ahammad F, Ahmed I, Bhuiyan MA, Asiri AM. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci Rep. 2021;11(1):4049.
   PubMed Web of Science ®Google Scholar
• Zheng L, Ren R, Sun X, Zou Y, Shi Y, Di B, Niu M-M. Discovery of a Dual Tubulin and Poly(ADP-Ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation. J Med Chem. 2021;64(21):15702–15715.
   PubMed Web of Science ®Google Scholar
• Niu M, Wang F, Li F, Dong Y, Gu Y. Establishment of a screening protocol for identification of aminopeptidase N inhibitors. J Taiwan Inst Chem Eng. 2015;49:19–26.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Di B, Niu MM. Structure-based pharmacophore design and virtual screening for novel tubulin inhibitors with potential anticancer activity. Molecules. 2019;24(17):24.
   Web of Science ®Google Scholar
• Fan J, Fu A, Zhang L. Progress in molecular docking. Quant Biol. 2019;7(2):83–89.
   Google Scholar
• Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. J Med Chem. 2014;57(8):3324–3341.
   PubMed Web of Science ®Google Scholar
• Ding L-Y, Hou Y-C, Kuo I-Y, Hsu T-Y, Tsai T-C, Chang H-W, Hsu W-Y, Tsao C-C, Tian C-C, Wang P-S, et al. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. Clin Epigenetics. 2020;12(1):87.
   PubMed Web of Science ®Google Scholar
• Gomha S, Salaheldin T, Hassaneen H, Abdel-Aziz H, Khedr M. Synthesis, characterization and molecular docking of novel bioactive thiazolyl-thiazole derivatives as promising cytotoxic antitumor drug. Molecules. 2015;21(1):E3.
   PubMed Web of Science ®Google Scholar
• Ahlina FN, Nugraheni N, Salsabila IA, Haryanti S, Da’i M, Meiyanto E. Revealing the reversal effect of Galangal (Alpinia galanga L.) extract against oxidative stress in metastatic breast cancer cells and normal fibroblast cells intended as a co-chemotherapeutic and anti-ageing agent. Asian Pac J Cancer Prev. 2020;21(1):107–117.
   PubMedGoogle Scholar